Prescient Therapeutics Limited (PTX.AX)
AUD 0.04
(0.0%)
AUD 0.04
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -10.16 Million AUD | -72.38% |
| 2023 | -5.89 Million AUD | 51.93% |
| 2022 | -12.26 Million AUD | 23.02% |
| 2021 | -15.93 Million AUD | -121.27% |
| 2020 | -7.2 Million AUD | 25.31% |
| 2019 | -9.63 Million AUD | -77.53% |
| 2018 | -5.42 Million AUD | 28.98% |
| 2017 | -7.64 Million AUD | 21.62% |
| 2016 | -9.75 Million AUD | -835.25% |
| 2015 | -1.04 Million AUD | 72.62% |
| 2014 | -3.8 Million AUD | 0.0% |
| 2013 | - AUD | -100.0% |
| 2012 | 1.07 Million AUD | 137.99% |
| 2011 | 450 Thousand AUD | 192.4% |
| 2010 | -487 Thousand AUD | -211.44% |
| 2009 | 437 Thousand AUD | 234.05% |
| 2008 | -326 Thousand AUD | 79.29% |
| 2007 | -1.57 Million AUD | 55.7% |
| 2006 | -3.55 Million AUD | -127.61% |
| 2005 | -1.56 Million AUD | -863.58% |
| 2004 | -162 Thousand AUD | 62.84% |
| 2003 | -436 Thousand AUD | -67.69% |
| 2002 | -260 Thousand AUD | -308.0% |
| 2001 | 125 Thousand AUD | 109.23% |
| 2000 | -1.35 Million AUD | 50.11% |
| 1999 | -2.71 Million AUD | -167.32% |
| 1998 | -1.01 Million AUD | -577.33% |
| 1997 | -150 Thousand AUD | -520.96% |
| 1996 | -24.15 Thousand AUD | -106.96% |
| 1995 | 347 Thousand AUD | -82.98% |
| 1994 | 2.03 Million AUD | 11.48% |
| 1993 | 1.82 Million AUD | -33.73% |
| 1992 | 2.76 Million AUD | 40.46% |
| 1991 | 1.96 Million AUD | 82.79% |
| 1990 | 1.07 Million AUD | -57.43% |
| 1989 | 2.52 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -10.16 Million AUD | 0.0% |
| 2024 Q2 | -6.41 Million AUD | 0.0% |
| 2024 FY | -10.16 Million AUD | -72.38% |
| 2023 FY | -5.89 Million AUD | 51.93% |
| 2023 Q2 | -20.95 Million AUD | 0.0% |
| 2023 Q4 | -5.89 Million AUD | 0.0% |
| 2022 FY | -12.26 Million AUD | 23.02% |
| 2022 Q2 | -14.76 Million AUD | 0.0% |
| 2022 Q4 | -12.26 Million AUD | 0.0% |
| 2021 Q4 | -15.93 Million AUD | 0.0% |
| 2021 FY | -15.93 Million AUD | -121.27% |
| 2021 Q2 | -18.44 Million AUD | 0.0% |
| 2020 FY | -7.2 Million AUD | 25.31% |
| 2020 Q2 | -5.71 Million AUD | 0.0% |
| 2020 Q4 | -7.2 Million AUD | 0.0% |
| 2019 FY | -9.63 Million AUD | -77.53% |
| 2019 Q4 | -9.63 Million AUD | 0.0% |
| 2019 Q2 | -3.3 Million AUD | 0.0% |
| 2018 FY | -5.42 Million AUD | 28.98% |
| 2018 Q4 | -5.42 Million AUD | 0.0% |
| 2018 Q2 | -5.98 Million AUD | 0.0% |
| 2017 FY | -7.64 Million AUD | 21.62% |
| 2017 Q4 | -7.64 Million AUD | 0.0% |
| 2017 Q2 | -5.92 Million AUD | 0.0% |
| 2016 FY | -9.75 Million AUD | -835.25% |
| 2016 Q2 | -1.92 Million AUD | 0.0% |
| 2016 Q4 | -9.75 Million AUD | 0.0% |
| 2015 FY | -1.04 Million AUD | 72.62% |
| 2015 Q2 | -2.32 Million AUD | 0.0% |
| 2015 Q4 | -1.04 Million AUD | 0.0% |
| 2014 Q4 | -3.8 Million AUD | 0.0% |
| 2014 FY | -3.8 Million AUD | 0.0% |
| 2014 Q2 | -1.51 Million AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q1 | - AUD | -100.0% |
| 2013 FY | - AUD | -100.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2012 FY | 1.07 Million AUD | 137.99% |
| 2012 Q4 | 1.07 Million AUD | 0.0% |
| 2011 FY | 450 Thousand AUD | 192.4% |
| 2011 Q4 | 450.88 Thousand AUD | 0.0% |
| 2010 FY | -487 Thousand AUD | -211.44% |
| 2010 Q4 | -486.87 Thousand AUD | 0.0% |
| 2009 Q4 | 437.65 Thousand AUD | 0.0% |
| 2009 FY | 437 Thousand AUD | 234.05% |
| 2008 FY | -326 Thousand AUD | 79.29% |
| 2008 Q4 | -326.43 Thousand AUD | 0.0% |
| 2007 FY | -1.57 Million AUD | 55.7% |
| 2007 Q4 | -1.57 Million AUD | 0.0% |
| 2006 Q4 | -3.55 Million AUD | 0.0% |
| 2006 FY | -3.55 Million AUD | -127.61% |
| 2005 FY | -1.56 Million AUD | -863.58% |
| 2005 Q4 | -4.11 Million AUD | 0.0% |
| 2004 Q4 | -3.81 Million AUD | 0.0% |
| 2004 FY | -162 Thousand AUD | 62.84% |
| 2003 FY | -436 Thousand AUD | -67.69% |
| 2003 Q4 | -1.53 Million AUD | 0.0% |
| 2002 FY | -260 Thousand AUD | -308.0% |
| 2002 Q4 | -1.82 Million AUD | 0.0% |
| 2001 FY | 125 Thousand AUD | 109.23% |
| 2001 Q4 | -3.73 Million AUD | 0.0% |
| 2000 Q4 | -1.35 Million AUD | 0.0% |
| 2000 FY | -1.35 Million AUD | 50.11% |
| 1999 Q4 | -2.71 Million AUD | 0.0% |
| 1999 FY | -2.71 Million AUD | -167.32% |
| 1998 FY | -1.01 Million AUD | -577.33% |
| 1997 FY | -150 Thousand AUD | -520.96% |
| 1997 Q4 | -150.26 Thousand AUD | 0.0% |
| 1996 FY | -24.15 Thousand AUD | -106.96% |
| 1995 FY | 347 Thousand AUD | -82.98% |
| 1994 FY | 2.03 Million AUD | 11.48% |
| 1993 FY | 1.82 Million AUD | -33.73% |
| 1992 FY | 2.76 Million AUD | 40.46% |
| 1991 FY | 1.96 Million AUD | 82.79% |
| 1990 FY | 1.07 Million AUD | -57.43% |
| 1989 FY | 2.52 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 46.226% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -934.785% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 300.553% |
| Biome Australia Limited | -1.56 Million AUD | -550.285% |
| Patrys Limited | -2.24 Million AUD | -353.558% |
| Orthocell Limited | -19.92 Million AUD | 48.995% |
| Imugene Limited | -91.56 Million AUD | 88.901% |
| Noxopharm Limited | -2.31 Million AUD | -338.061% |
| PYC Therapeutics Limited | -65.76 Million AUD | 84.546% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -232.876% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -60.704% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -63.771% |
| CSL Limited | 15.76 Billion AUD | 100.064% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 20.069% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -1332.257% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 94.446% |
| Starpharma Holdings Limited | -19.83 Million AUD | 48.756% |
| Nanollose Limited | -96.22 Thousand AUD | -10461.389% |
| Memphasys Limited | 4.13 Million AUD | 345.75% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -68.674% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -105.135% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -457.29% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 87.186% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -720.625% |
| Race Oncology Limited | -17.18 Million AUD | 40.876% |
| Nyrada Inc. | -4.76 Million AUD | -113.082% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 90.394% |
| Dimerix Limited | -21.99 Million AUD | 53.789% |
| PharmAust Limited | -9.71 Million AUD | -4.618% |
| Immutep Limited | -122.18 Million AUD | 91.683% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 92.555% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 18.567% |
| BTC Health Limited | -2.02 Million AUD | -402.568% |
| Acrux Limited | -1.45 Million AUD | -597.03% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 40.548% |
| Biotron Limited | -386.06 Thousand AUD | -2532.359% |
| Tissue Repair Ltd | -16.44 Million AUD | 38.187% |
| AdAlta Limited | -845.17 Thousand AUD | -1102.44% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 45.288% |
| Hexima Limited | -2.22 Million AUD | -356.501% |
| AnteoTech Limited | -5 Million AUD | -103.192% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 42.197% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -199.243% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -90.697% |
| Actinogen Medical Limited | -9.13 Million AUD | -11.291% |
| Immuron Limited | -11.48 Million AUD | 11.504% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 36.135% |